List of Excipients in Branded Drug ZERVIATE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Eyevance Pharmaceuticals	ZERVIATE	cetirizine	71776-024	BENZALKONIUM CHLORIDE
Eyevance Pharmaceuticals	ZERVIATE	cetirizine	71776-024	EDETATE DISODIUM
Eyevance Pharmaceuticals	ZERVIATE	cetirizine	71776-024	GLYCERIN
Eyevance Pharmaceuticals	ZERVIATE	cetirizine	71776-024	HYDROCHLORIC ACID

Zerviate Excipient Strategy and Commercial Opportunities

Last updated: October 25, 2026

Zerviate is cetirizine hydrochloride ophthalmic solution 0.24%, an FDA-approved, preservative-free topical antihistamine for ocular itching associated with allergic conjunctivitis. Its commercial opportunity depends less on active-ingredient exclusivity and more on preservative-free delivery, ocular tolerability, sterile manufacturing, dispensing convenience, and differentiation from olopatadine, ketotifen, and other allergy eye drops. Zerviate was approved under NDA 210514 in 2017 and is indicated for patients aged 2 years and older.[1]

What excipients are used in Zerviate?

Zerviate uses a conventional buffered, isotonic aqueous ophthalmic system designed to solubilize cetirizine hydrochloride while controlling pH, tonicity, metal-ion contamination, and ocular comfort.

Excipient	Functional role
Glycerin	Tonicity adjustment and ocular comfort
Sodium chloride	Osmolality control
Sodium phosphate dibasic heptahydrate	Buffer capacity and pH control
Sodium phosphate monobasic monohydrate	Buffer capacity and pH control
Disodium edetate dihydrate	Chelation and control of trace-metal-driven degradation
Hydrochloric acid and/or sodium hydroxide	Final pH adjustment
Water for injection	Sterile aqueous vehicle

The labeling identifies Zerviate as preservative-free. The formulation does not rely on benzalkonium chloride, a preservative associated with ocular-surface irritation and epithelial toxicity in chronic or repeated-use settings.[1][2]

The excipient system is commercially important because cetirizine is delivered directly to the ocular surface rather than systemically. The formulation must maintain chemical stability, sterility, suitable osmolality, acceptable pH, low particulate burden, and tolerability during repeated dosing.

Why is the preservative-free formulation commercially important?

Preservative-free delivery is Zerviate’s clearest formulation-based commercial differentiator.

Patients with seasonal allergic conjunctivitis may dose for several weeks, and some have pre-existing dry eye, contact-lens intolerance, blepharitis, or ocular-surface disease. Removing benzalkonium chloride supports positioning for these patients and for prescribers who avoid preserved topical products.

The opportunity is strongest in four segments:

1. Patients requiring repeated seasonal use.
2. Patients with ocular-surface sensitivity or dry eye.
3. Pediatric patients aged 2 years and older.
4. Contact-lens wearers who prefer preservative-free products, subject to label instructions.

Preservative-free status alone does not guarantee market share. Zerviate must compete against products with strong physician familiarity, established payer coverage, once-daily dosing, and broad retail distribution. Its value proposition is strongest when the prescriber prioritizes ocular-surface tolerability and a non-steroidal topical antihistamine.

How does Zerviate compare with competing allergy eye drops?

Zerviate competes in a crowded ophthalmic allergy market that includes antihistamine-only products, dual-action antihistamine/mast-cell stabilizers, and over-the-counter products.

Product or class	Active ingredient	Preservative-free positioning	Typical dosing advantage	Commercial implication
Zerviate	Cetirizine 0.24%	Yes	Twice daily	Differentiates on preservative-free cetirizine delivery
Pataday	Olopatadine	Certain presentations are preservative-free	Once daily for some strengths	Strong convenience and consumer recognition
Pazeo	Olopatadine 0.7%	Product-specific	Once daily	Strong duration-of-action positioning
Zaditor/Alaway	Ketotifen	Product-specific	Twice daily	Established OTC access and price pressure
Bepreve	Bepotastine	Product-specific	Twice daily	Prescription antihistamine alternative
Lastacaft	Alcaftadine	Preservative-free presentation	Once daily	Direct premium prescription competitor

Zerviate’s main commercial disadvantage is twice-daily administration when several competing products promote once-daily use. Its main advantages are cetirizine-based pharmacology, preservative-free formulation, pediatric labeling, and a differentiated active ingredient in a familiar allergy category.

The product is therefore more likely to win through targeted prescribing than through broad substitution across the entire allergy market.

What formulation patents and intellectual-property barriers protect Zerviate?

The active ingredient, cetirizine, is an established antihistamine with no meaningful new-molecule exclusivity remaining. Zerviate’s defensibility must therefore come from formulation, use, delivery, manufacturing, and commercial know-how.

Composition and formulation protection

Potential claim categories for a cetirizine ophthalmic product include:

• Cetirizine concentration in an ophthalmically acceptable aqueous vehicle.
• Preservative-free formulations.
• Buffer and tonicity combinations.
• pH ranges that balance solubility, comfort, and stability.
• Chelator-containing systems.
• Container-closure configurations.
• Sterile manufacturing and filling processes.
• Methods of treating ocular itching with topical cetirizine.

These claims can create barriers even when the active ingredient is old. Their strength depends on claim scope, written-description support, prosecution history, patent-family continuity, and whether a generic can design around the claimed excipient ranges.

A competitor could attempt to use the same 0.24% cetirizine concentration with a different buffer, tonicity agent, chelator, container, or pH profile. That creates a design-around pathway unless the relevant claims cover the broader functional combination rather than a narrow excipient recipe.

Trade secrets and manufacturing know-how

The most durable non-patent barriers are likely to involve:

• Sterile filtration parameters.
• Dissolution and mixing order.
• Control of cetirizine crystallization or precipitation.
• Hold-time controls.
• Container-closure compatibility.
• Particulate control.
• Filling-line yield.
• Preservative-free multidose handling, where applicable.
• Stability protocols for commercial packaging.

These process elements may not block a generic legally, but they can increase development time, batch-failure risk, and regulatory burden.

When does Zerviate lose exclusivity?

Zerviate’s regulatory exclusivity is distinct from patent protection.

Exclusivity category	Zerviate position
New chemical entity exclusivity	Not available because cetirizine was previously approved
Three-year clinical-investigation exclusivity	Potentially relevant to the 2017 approval pathway, but expired
Pediatric exclusivity	Depends on an FDA grant tied to completed written-request studies; no current extension should be assumed without an applicable FDA record
Orphan exclusivity	Not applicable
Patent exclusivity	Depends on issued and listed formulation, method, or delivery patents
Regulatory pathway	Generic applicants may pursue an ANDA if the reference-product requirements are met

Zerviate’s five-year new chemical entity exclusivity did not apply because the product contains an established active ingredient. Any three-year exclusivity associated with new clinical investigations would have expired several years ago.[1][3]

The practical generic-entry date is therefore controlled by the live patent estate, Orange Book listings, litigation, settlement agreements, and FDA approval timing rather than by the original approval date alone.

What is the Orange Book status of Zerviate?

Zerviate is identified by FDA as a prescription ophthalmic product under NDA 210514. The Orange Book is the controlling source for current listed patents, expiration dates, and any pediatric-exclusivity notation.[3]

For commercial planning, the relevant Orange Book questions are:

• Whether formulation patents are listed against NDA 210514.
• Whether method-of-use patents are listed.
• Whether any listed patents have expired.
• Whether a patent has a pediatric extension.
• Whether an ANDA applicant has submitted a Paragraph IV certification.
• Whether patent litigation has triggered a 30-month stay.
• Whether an authorized generic or settlement agreement affects launch timing.

A label review alone cannot establish current patent scope. Orange Book listings must be assessed against the patent family, claim language, terminal disclaimers, expiration calculations, and any FDA delisting decisions.

Which companies are challenging Zerviate’s market position?

Zerviate faces competition from branded prescription products, over-the-counter allergy drops, and potential generic cetirizine ophthalmic products.

Branded competitors

The principal branded competitors include products containing olopatadine, alcaftadine, bepotastine, and ketotifen. Olopatadine is the most important commercial comparator because it combines strong physician recognition with once-daily products and broad payer familiarity.

Over-the-counter competitors

Ketotifen products create substantial price pressure. Their availability without a prescription reduces the addressable market for premium prescription antihistamine drops, particularly for mild disease.

Generic competitors

A generic applicant would likely evaluate three routes:

1. An ANDA referencing Zerviate if the product-specific requirements are met.
2. A 505(b)(2) application if formulation or clinical differences prevent a conventional ANDA.
3. A reformulated cetirizine ophthalmic product with a non-infringing excipient system.

The largest technical challenge is not cetirizine synthesis. It is proving pharmaceutical equivalence, stability, sterility, container compatibility, and comparable ophthalmic performance in a preservative-free product.

What Paragraph IV challenges and litigation risks exist?

A Paragraph IV challenge would be commercially significant only if Zerviate has unexpired Orange Book-listed patents. The likely attack points would include:

• Lack of patentable distinction over known cetirizine ophthalmic formulations.
• Obviousness based on known ophthalmic buffers, tonicity agents, and chelators.
• Narrow claim construction around excipient concentration ranges.
• Design-around using a different buffer or pH.
• Invalidity based on prior cetirizine ophthalmic formulations.
• Non-infringement based on a different container or manufacturing process.

The sponsor’s strongest litigation position would arise from claims that cover the formulation as a functional combination, not merely a specific list of routine excipients. Claims limited to conventional buffer and tonicity ingredients are more exposed to obviousness and design-around arguments.

No commercial forecast should assume an unobstructed generic launch merely because cetirizine is old. Conversely, no delayed-entry forecast should assume that a formulation patent will block all alternatives. The outcome depends on the exact listed claims and the applicant’s certification.

What excipient opportunities exist around Zerviate?

Zerviate creates several development and licensing opportunities for excipient suppliers, ophthalmic manufacturers, and specialty pharmaceutical companies.

Preservative-free multidose delivery

A commercially attractive opportunity is a multidose container that maintains microbial protection without benzalkonium chloride or other conventional preservatives. Potential technologies include:

• One-way valve systems.
• Airless dispensing systems.
• Sterile unit-dose presentations.
• Tip-protection technologies.
• Low-residual-volume bottles.
• Metered-dose ophthalmic pumps.

The economic value depends on whether the delivery system reduces waste, improves dose consistency, and supports reimbursement or premium pricing.

Unit-dose packaging

Unit-dose Zerviate could target:

• Pediatric use.
• Travel and seasonal use.
• Patients with severe preservative sensitivity.
• Clinics and samples.
• High-compliance specialty channels.

The disadvantages are higher packaging cost, more material per administered dose, increased logistics expense, and greater environmental burden.

Improved comfort systems

A reformulated product could evaluate alternative tonicity agents, buffer systems, or comfort-enhancing excipients. Any change must preserve cetirizine solubility, chemical stability, sterility, and ocular tolerability.

Possible development objectives include:

• Lower stinging on instillation.
• Improved comfort at the ocular surface.
• Reduced transient blur.
• Longer residence time.
• Lower dosing frequency.
• Better compatibility with contact-lens use, if supported by labeling.

Each change could create a new patent opportunity, but it would also increase regulatory complexity and may move the product away from a simple generic-equivalent strategy.

Bioadhesive or sustained-release systems

A sustained-release cetirizine ophthalmic product could seek once-daily or less frequent dosing. Candidates may include in situ gels, mucoadhesive polymers, lipid systems, or particulate carriers.

The commercial upside is substantial because dosing frequency is one of Zerviate’s main competitive weaknesses. The development risks include blurred vision, altered drug exposure, ocular-surface residence, manufacturing complexity, and a likely 505(b)(2) regulatory pathway rather than a straightforward ANDA.

How strong is the Zerviate patent estate?

Zerviate has moderate potential formulation defensibility but limited active-ingredient exclusivity.

Factor	Assessment
Active-ingredient protection	Weak; cetirizine is an established molecule
Regulatory exclusivity	Expired or no longer central to entry analysis
Preservative-free positioning	Commercially strong, but not automatically patent-blocking
Excipient combination	Potentially protectable if claims are specific and non-obvious
Manufacturing know-how	Potentially meaningful operational barrier
Generic design-around risk	Moderate to high
Biosimilar risk	Not applicable
Long-term moat	Dependent on formulation patents, device IP, brand, and payer access

The patent estate is more vulnerable than that of a new chemical entity or biologic. Its value lies in delaying direct copies and supporting differentiated reformulations, not in preventing all cetirizine ophthalmic competition indefinitely.

What generic launch scenarios exist?

Scenario 1: No blocking listed patent

A qualified ANDA applicant could pursue approval after satisfying FDA requirements for pharmaceutical equivalence and bioequivalence. Launch could follow FDA approval, subject to manufacturing readiness and commercial contracting.

Scenario 2: Paragraph IV challenge

An applicant certifies that listed patents are invalid, unenforceable, or not infringed. Litigation may trigger a 30-month stay, creating a potential launch date based on the court outcome, settlement terms, or statutory timing.

Scenario 3: Paragraph III certification

The applicant accepts a listed patent and waits for its expiration. This is the lowest-litigation pathway but may delay entry.

Scenario 4: 505(b)(2) reformulation

A company develops a differentiated preservative-free, once-daily, or sustained-release product. This approach may create new intellectual property but requires additional clinical or bridging evidence.

What licensing deals affect Zerviate?

Zerviate was developed by Nicox and commercialized in the United States through a licensing arrangement with Eyevance Pharmaceuticals. Eyevance was later acquired by Santen, creating a chain of commercial-rights transfers relevant to royalty economics and regional control.[4][5]

Licensing diligence should focus on:

• Territory-by-territory rights.
• Royalty rates and milestone obligations.
• Minimum sales or diligence requirements.
• Rights to improvements and reformulations.
• Control of patent prosecution.
• Responsibility for pharmacovigilance.
• Manufacturing and supply obligations.
• Rights after termination.
• Existing sub-license arrangements.

The commercial value of any new excipient or device partnership will depend on whether it improves dosing frequency, tolerability, supply economics, or patent duration without creating a costly regulatory reset.

What is the revenue exposure for Zerviate?

Product-level revenue is not consistently disclosed as a standalone figure in public company reporting. Revenue exposure is therefore best assessed through market position rather than a single reported sales number.

The key revenue drivers are:

• Prescription allergy-season demand.
• Payer coverage and formulary tier.
• Copay support.
• Retail availability.
• Prescriber awareness.
• Pediatric use.
• Preservative-free substitution.
• Competition from OTC ketotifen.
• Once-daily alternatives.
• Generic entry timing.

The highest-value commercial opportunity is a differentiated product that retains cetirizine’s topical identity while reducing dosing frequency or improving dispensing convenience. A low-cost generic strategy could capture volume but would face price competition from existing allergy products. A premium formulation strategy has more margin potential but requires clinical differentiation.

Key Takeaways

• Zerviate is a preservative-free cetirizine ophthalmic solution 0.24% approved for ocular itching associated with allergic conjunctivitis.
• Its excipient system uses glycerin, sodium chloride, phosphate buffers, disodium edetate, water for injection, and pH adjusters.
• The commercial advantage is preservative-free delivery, not new-molecule exclusivity.
• Cetirizine’s established status leaves formulation, method-of-use, device, and manufacturing IP as the main protection layers.
• Twice-daily dosing is Zerviate’s principal competitive weakness against once-daily olopatadine and alcaftadine products.
• The strongest reformulation opportunity is a once-daily or sustained-release preservative-free product.
• A generic could pursue an ANDA, while a differentiated reformulation may require a 505(b)(2) pathway.
• Biosimilar risk is not relevant because Zerviate is a small-molecule ophthalmic product.
• Current Paragraph IV and launch-risk conclusions depend on live Orange Book listings and applicable patent litigation.
• Excipient and container-closure partnerships can create commercial value if they improve comfort, dosing frequency, sterility assurance, or supply economics.

FAQs

Is Zerviate preservative-free?

Yes. Zerviate is labeled as a preservative-free ophthalmic solution, which supports use in patients concerned about ocular-surface irritation from conventional preservatives.[1]

Can a generic use the same Zerviate excipients?

A generic may use the same or different inactive ingredients, subject to FDA pharmaceutical-equivalence, quality, safety, and product-specific requirements. The formulation must also avoid infringing unexpired listed patent claims.

Is cetirizine ophthalmic solution a biologic?

No. Zerviate is a small-molecule ophthalmic drug. Biosimilar pathways do not apply.

What is the best commercial reformulation opportunity for Zerviate?

A once-daily preservative-free formulation is the clearest opportunity because it addresses Zerviate’s main disadvantage against competing allergy drops while preserving its ocular-surface positioning.

Can Zerviate be converted into an over-the-counter product?

Potentially, but an OTC switch would require FDA review of labeling, consumer self-selection, safety, dosing, and nonprescription-use conditions. The prescription-to-OTC pathway would be commercially material but is not automatic.

References

1. U.S. Food and Drug Administration. (2017). Zerviate (cetirizine hydrochloride ophthalmic solution) 0.24% prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Inactive ingredient database. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

4. Nicox S.A. (2017). Annual report and corporate disclosures regarding Zerviate licensing and commercialization. Nicox.

5. Santen Pharmaceutical Co., Ltd. (2020). Corporate announcement regarding the acquisition of Eyevance Pharmaceuticals. Santen.